{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:14:57Z","timestamp":1762866897047},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ijid.2016.06.016","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T21:19:23Z","timestamp":1466630363000},"page":"141-148","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010\u20132014"],"prefix":"10.1016","volume":"49","author":[{"given":"Maria","family":"T\u00e4rnberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennart E.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Dowzicky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2016.06.016_bib0185","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkg466","article-title":"Managing skin and soft tissue infections: expert panel recommendations on key decision points","volume":"52","author":"Eron","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2016.06.016_bib0190","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1093\/jac\/dkh202","article-title":"Complicated infections of skin and skin structures: when the infection is more than skin deep","volume":"53","author":"DiNubile","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2016.06.016_bib0195","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1201-9712(07)60002-2","article-title":"Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections","volume":"11","author":"Grolman","year":"2007","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0200","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0205","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/520743","article-title":"Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes","volume":"28","author":"Lipsky","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijid.2016.06.016_bib0210","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/526444","article-title":"Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections","volume":"29","author":"Edelsberg","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijid.2016.06.016_bib0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0732-8893(02)00543-6","article-title":"Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)","volume":"45","author":"Rennie","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0220","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.diagmicrobio.2009.02.005","article-title":"The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study","volume":"64","author":"Hatoum","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0225","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/1471-2334-14-476","article-title":"Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe","volume":"14","author":"Nathwani","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0230","series-title":"Tygacil\u00ae package insert","year":"2013"},{"key":"10.1016\/j.ijid.2016.06.016_bib0235","unstructured":"European Medicines Agency, Science Medicines Health. Tygacil (tigecycline) update. European Medicines Agency; 2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000644\/WC500044509.pdf.(accessed September 28, 2015)."},{"key":"10.1016\/j.ijid.2016.06.016_bib0240","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.ijid.2011.09.021","article-title":"Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline Evaluation and Surveillance Trial, 2004-2009","volume":"16","author":"Namdari","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0245","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard","year":"2009"},{"key":"10.1016\/j.ijid.2016.06.016_bib0250","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2047-2994-3-36","article-title":"A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012","volume":"3","author":"Cattoir","year":"2014","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijid.2016.06.016_bib0255","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2015"},{"key":"10.1016\/j.ijid.2016.06.016_bib0260","series-title":"Tygacil\u00ae product insert","year":"2011"},{"key":"10.1016\/j.ijid.2016.06.016_bib0265","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijantimicag.2010.03.016","article-title":"Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres","volume":"36","author":"Sader","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2016.06.016_bib0270","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/MCC.0b013e32834c9d87","article-title":"Recent trends in antibiotic resistance in European ICUs","volume":"17","author":"van Duijn","year":"2011","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.ijid.2016.06.016_bib0275","series-title":"Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","article-title":"Antimicrobial resistance surveillance in Europe 2012","year":"2013"},{"key":"10.1016\/j.ijid.2016.06.016_bib0280","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jac\/dkn149","article-title":"Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study","volume":"62","author":"Tillotson","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2016.06.016_bib0285","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2014.04.007","article-title":"Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria","volume":"44","author":"Eckmann","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2016.06.016_bib0290","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.diagmicrobio.2014.01.017","article-title":"In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012","volume":"79","author":"Renteria","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0295","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/650574","article-title":"Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus","volume":"50","author":"Morales","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0300","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.2010.757","article-title":"Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit","volume":"303","author":"S\u00e1nchez Garcia","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2016.06.016_bib0305","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.diagmicrobio.2009.10.011","article-title":"Linezolid surveillance program results for 2008 (LEADER Program for 2008)","volume":"65","author":"Farrell","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0310","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.diagmicrobio.2009.03.001","article-title":"ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries","volume":"64","author":"Jones","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0315","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1179\/joc.2011.23.2.71","article-title":"Eight-year (2002-2009) summary of the linezolid (Zyvox\u00ae Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries","volume":"23","author":"Ross","year":"2011","journal-title":"J Chemother"},{"key":"10.1016\/j.ijid.2016.06.016_bib0320","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/jac\/dkt541","article-title":"Zyvox\u00ae Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12)","volume":"69","author":"Mendes","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2016.06.016_bib0325","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2005.05.005","article-title":"Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0330","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijantimicag.2012.10.014","article-title":"Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010","volume":"41","author":"Hawser","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2016.06.016_bib0335","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1128\/AAC.00070-11","article-title":"Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates","volume":"55","author":"Hawser","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2016.06.016_bib0340","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2016.06.016_bib0345","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy","volume":"8","author":"Zavascki","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2016.06.016_bib0350","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.diagmicrobio.2012.04.007","article-title":"Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010)","volume":"73","author":"Gales","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0355","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.diagmicrobio.2007.09.006","article-title":"Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results","volume":"60","author":"Turner","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2016.06.016_bib0360","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000351098","article-title":"Acinetobacter baumannii infections in a tertiary care hospital in Mexico over the past 13 years","volume":"59","author":"Morf\u00edn-Otero","year":"2013","journal-title":"Chemotherapy"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971216311018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971216311018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T02:52:05Z","timestamp":1536634325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971216311018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":36,"alternative-id":["S1201971216311018"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2016.06.016","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010\u20132014","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2016.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}